AMG 609
Alternative Names: AMG-609Latest Information Update: 08 Aug 2023
Price :
$50 *
At a glance
- Originator Amgen
- Class Hepatoprotectants; Small interfering RNA
- Mechanism of Action Adiponutrin modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 08 Aug 2023 Discontinued - Phase-I for Non-alcoholic fatty liver disease in USA (SC) (Amgen pipeline, August 2023)
- 08 Aug 2023 Discontinued - Phase-I for Non-alcoholic steatohepatitis in USA (SC) (Amgen pipeline, August 2023)
- 17 Jul 2023 Amgen completes a Phase-I clinical trials in Non-alcoholic fatty liver disease in USA (SC) (NCT04857606)